docetaxel anhydrous has been researched along with Rhabdoid Tumor in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Fujisaki, H; Hara, J; Hira, K; Ishii, Y; Matsubara, K; Nitani, C; Okada, K; Okuhiro, Y; Tanimura, K; Yamasaki, K | 1 |
| Bobilev, D; Ditzler, S; Eslamy, H; Girard, E; Lee, D; Olson, J; Park, J; Richards, A; Vrignaud, P; Yagle, K | 1 |
2 other study(ies) available for docetaxel anhydrous and Rhabdoid Tumor
| Article | Year |
|---|---|
[Gemcitabine and Docetaxel for the Treatment of Relapsed and Refractory Malignant Rhabdoid Tumor of Kidney and Atypical Teratoid Rhabdoid Tumor].
Topics: Deoxycytidine; Docetaxel; Gemcitabine; Humans; Kidney; Rhabdoid Tumor; SMARCB1 Protein; Teratoma | 2021 |
Efficacy of cabazitaxel in mouse models of pediatric brain tumors.
Topics: Animals; Antineoplastic Agents; Brain Neoplasms; Disease Models, Animal; Docetaxel; Drug Evaluation, Preclinical; Female; Humans; Male; Maximum Tolerated Dose; Medulloblastoma; Mice; Mice, Inbred C57BL; Mice, Nude; Neuroectodermal Tumors; Rhabdoid Tumor; Survival Analysis; Taxoids; Teratoma; Treatment Outcome; Xenograft Model Antitumor Assays | 2015 |